Results 21 to 30 of about 14,520 (202)

Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy

Breast Cancer Research, 2023
Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infiltrating ...
Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler   +10 more
doaj   +1 more source

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Медицинский совет, 2021
Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy.
D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, L. G. Zhukova   +7 more
doaj   +1 more source

Fulvestrant for the treatment of advanced breast cancer [PDF]

, 2018
Introduction: The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader
Blackburn, Sophie A., Kwok-Leung Cheung, Cheung, Kwok-Leung, Ruth M. Parks, Parks, Ruth M., Sophie A. Blackburn   +5 more
core   +1 more source

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

Molecular Oncology, 2016
Fulvestrant is a dose dependent selective estrogen receptor (ER) down‐regulator (SERD) used in ER‐positive metastatic breast cancer (MBC). Nearly all patients develop resistance.
Costanza Paoletti, Jose M. Larios, Maria C. Muñiz, Kimberly Aung, Emily M. Cannell, Elizabeth P. Darga, Kelley M. Kidwell, Dafydd G. Thomas, Nahomi Tokudome, Martha E. Brown, Mark C. Connelly, David A. Chianese, Anne F. Schott, N. Lynn Henry, James M. Rae, Daniel F. Hayes   +15 more
doaj   +1 more source

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis

BMC Cancer, 2023
Background This network meta-analysis aimed to assess the comparative efficacy and safety of combinations involving three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapies (ETs) in patients with metastatic or advanced breast cancer (
Yiyuan Liu, Jinyao Wu, Zeqi Ji, Lingzhi Chen, Juan Zou, Jiehua Zheng, Weixun Lin, Jiehui Cai, Yaokun Chen, Daitian Zheng, Yexi Chen, Zhiyang Li   +11 more
doaj   +1 more source

A good drug made better: the Fulvestrant Dose Response Story [PDF]

, 2014
Sequential use of endocrine therapies remains the cornerstone of treatment for hormone receptor-positive advanced breast cancer, prior to use of cytotoxic chemotherapy for unresponsive disease. Fulvestrant is an estrogen receptor (ER) antagonist approved
Garnett, Sally, Gee, Julia Margaret Wendy, Robertson, John F.R., Anderson, Elizabeth, Lindemann, Justin, Nicholson, Robert I., Kuter, Irene   +6 more
core   +1 more source

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer [PDF]

, 2018
BACKGROUND The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2 ...
Masuda, Norikazu, Iwata, H, Loi, S, Verma, S, Puyana Theall, K, Harbeck, N, André, F, Bondarenko, I, Huang, X., Slamon, Dennis J., Iwata, H., Harbeck, Nadia, Slamon, D.J., Cristofanilli, M, Colleoni, Marco, DeMichele, A, Bondarenko, I., Im, S.-A., DeMichele, A., Loibl, S, Turner, Nicholas C., Verma, Sunil, Turner, N.C., Im, S-A, Huang Bartlett, C., Loi, Sherene, Andre, Fabrice, Ro, Jungsil, Giorgetti, Carla, Loibl, S., Cristofanilli, Massimo, Verma, S., Colleoni, M, Huang Bartlett, C, Loi, S., André, F., Masuda, N, Masuda, N., Giorgetti, C., Bondarenko, Igor, Cristofanilli, M., Colleoni, M., Puyana Theall, K., Giorgetti, C, DeMichele, Angela, Huang, X, Harbeck, N., Slamon, DJ, Ro, J., Ro, J, Loibl, Sibylle, Huang, Xin, Iwata, Hiroji, Turner, NC, Bartlett, C. Huang, Theall, K. Puyana, Im, Seock-Ah   +56 more
core   +1 more source

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Nature Communications, 2016
Fulvestrant degrades the oestrogen receptor. Here, the authors report on a clinical trial using fulvestrant and show that mutations in the oestrogen receptor alpha gene are prevalent in circulating tumour DNA and do not influence the clinical outcome of ...
Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Jiaheng Qiu, Timothy R. Wilson, Heidi Savage, Junko Aimi, Mika K. Derynck, Meng Chen, Iris T. Chan, Lukas C. Amler, Garret M. Hampton, Stephen Johnston, Ian Krop, Peter Schmid, Mark R. Lackner   +15 more
doaj   +1 more source

Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis

Journal of Pharmacological Sciences, 2015
Previous studies demonstrated that sulfate conjugation is involved in the metabolism of three commonly used breast cancer drugs, tamoxifen, raloxifene and fulvestrant.
Ying Hui, Lijun Luo, Lingtian Zhang, Katsuhisa Kurogi, Chunyang Zhou, Yoichi Sakakibara, Masahito Suiko, Ming-Cheh Liu   +7 more
doaj   +1 more source